709 related articles for article (PubMed ID: 2226914)
21. Response to intermittent RU486 in women.
Spitz IM; Croxatto HB; Salvatierra AM; Heikinheimo O
Fertil Steril; 1993 May; 59(5):971-5. PubMed ID: 8486197
[TBL] [Abstract][Full Text] [Related]
22. Estrogen induces premature luteal regression in rhesus monkeys during spontaneous menstrual cycles, but not in cycles driven by exogenous gonadotropin-releasing hormone.
Hutchison JS; Kubik CJ; Nelson PB; Zeleznik AJ
Endocrinology; 1987 Aug; 121(2):466-74. PubMed ID: 3297646
[TBL] [Abstract][Full Text] [Related]
23. Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: a potential new contraceptive strategy.
Batista MC; Cartledge TP; Zellmer AW; Merino MJ; Axiotis C; Loriaux DL; Nieman LK
Am J Obstet Gynecol; 1992 Jul; 167(1):60-5. PubMed ID: 1442957
[TBL] [Abstract][Full Text] [Related]
24. The induction of premature luteolysis in normal women--follicular phase luteinizing hormone secretion and corpus luteum function in the subsequent cycle.
Soules MR; Bremner WJ; Dahl KD; Rivier JE; Vale WW; Clifton DK
Am J Obstet Gynecol; 1991 Apr; 164(4):989-94; discussion 994-6. PubMed ID: 2014851
[TBL] [Abstract][Full Text] [Related]
25. Acute effects of progesterone and the antiprogestin RU 486 on gonadotropin secretion in the follicular phase of the menstrual cycle.
Permezel JM; Lenton EA; Roberts I; Cooke ID
J Clin Endocrinol Metab; 1989 May; 68(5):960-5. PubMed ID: 2497130
[TBL] [Abstract][Full Text] [Related]
26. Ablation of folliculogenesis in women by a single dose of gonadotropin-releasing hormone agonist: significance of time in cycle.
Monroe SE; Henzl MR; Martin MC; Schriock E; Lewis V; Nerenberg C; Jaffe RB
Fertil Steril; 1985 Mar; 43(3):361-8. PubMed ID: 3156770
[TBL] [Abstract][Full Text] [Related]
27. Effect of tamoxifen alone and in combination with RU 486 on the endometrium in the mid-luteal phase.
Swahn ML; Bygdeman M; Seppälä M; Johannisson E; Cekan S
Hum Reprod; 1993 Feb; 8(2):193-200. PubMed ID: 8473418
[TBL] [Abstract][Full Text] [Related]
28. The effects of progesterone receptor blockade in the luteal phase of normal fertile women.
Li TC; Dockery P; Thomas P; Rogers AW; Lenton EA; Cooke ID
Fertil Steril; 1988 Nov; 50(5):732-42. PubMed ID: 3181485
[TBL] [Abstract][Full Text] [Related]
29. The dependency of folliculogenesis and corpus luteum function on pulsatile gonadotropin secretion in cycling women using a gonadotropin-releasing hormone antagonist as a probe.
Mais V; Kazer RR; Cetel NS; Rivier J; Vale W; Yen SS
J Clin Endocrinol Metab; 1986 Jun; 62(6):1250-5. PubMed ID: 3084538
[TBL] [Abstract][Full Text] [Related]
30. Follicular arrest during the midfollicular phase of the menstrual cycle: a gonadotropin-releasing hormone antagonist imposed follicular-follicular transition.
Kettel LM; Roseff SJ; Chiu TC; Bangah ML; Vale W; Rivier J; Burger HG; Yen SS
J Clin Endocrinol Metab; 1991 Sep; 73(3):644-9. PubMed ID: 1908486
[TBL] [Abstract][Full Text] [Related]
31. Hypersensitivity of the human gonadotrophs to the repeated administration of small doses of LH-RH.
Faure N; Olivier GC
Horm Res; 1978; 9(1):12-21. PubMed ID: 338460
[TBL] [Abstract][Full Text] [Related]
32. Early follicular phase luteinizing hormone-releasing hormone agonist administration - effects on follicular maturation and corpus luteum function in women.
Skarin G; Nillius SJ; Wide L
Contraception; 1982 Jan; 25(1):31-9. PubMed ID: 6800690
[TBL] [Abstract][Full Text] [Related]
33. Effects of a luteinizing hormone-releasing hormone agonist on luteal function in women.
Bergquist C; Nillius SJ; Wide L
Contraception; 1980 Sep; 22(3):287-93. PubMed ID: 7002443
[TBL] [Abstract][Full Text] [Related]
34. Effects of a superactive luteinizing hormone-releasing factor agonist on gonadotropin and ovarian function during the menstrual cycle.
Sheehan KL; Casper RF; Yen SS
Am J Obstet Gynecol; 1979 Nov; 135(6):759-63. PubMed ID: 386801
[TBL] [Abstract][Full Text] [Related]
35. [Mechanism of LH release with synthetic LH-RH (author's transl)].
Koyama T
Nihon Naibunpi Gakkai Zasshi; 1976 Sep; 52(9):881-97. PubMed ID: 828583
[TBL] [Abstract][Full Text] [Related]
36. The use of anti-progesterones as a medical IUD.
Nieman LK; Loriaux DL
Baillieres Clin Obstet Gynaecol; 1988 Sep; 2(3):609-16. PubMed ID: 3233821
[TBL] [Abstract][Full Text] [Related]
37. The importance of luteinizing hormone in the control of inhibin and progesterone secretion by the human corpus luteum.
McLachlan RI; Cohen NL; Vale WW; Rivier JE; Burger HG; Bremner WJ; Soules MR
J Clin Endocrinol Metab; 1989 Jun; 68(6):1078-85. PubMed ID: 2498381
[TBL] [Abstract][Full Text] [Related]
38. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation.
Gemzell-Danielsson K; Swahn ML; Svalander P; Bygdeman M
Hum Reprod; 1993 Jun; 8(6):870-3. PubMed ID: 8345076
[TBL] [Abstract][Full Text] [Related]
39. Dynamics of circulating concentrations of gonadotropins and ovarian hormones throughout the menstrual cycle in the bonnet monkey: role of inhibin A in the regulation of follicle-stimulating hormone secretion.
Suresh PS; Medhamurthy R
Am J Primatol; 2009 Oct; 71(10):817-24. PubMed ID: 19452529
[TBL] [Abstract][Full Text] [Related]
40. The rhesus monkey corpus luteum is dependent on pituitary gonadotropin secretion throughout the luteal phase of the menstrual cycle.
Hutchison JS; Zeleznik AJ
Endocrinology; 1984 Nov; 115(5):1780-6. PubMed ID: 6436009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]